BIOBADASAR study of cancer risk in RA patients with prev cancer treated with b/tsDMARD. No increased risk, but yet again abatacept numbers are making me slightly nervous! @rheumnow #ACR22 Abstr#0267 https://t.co/H8gYm9STT3 https://t.co/sEIS6Ljwao

• Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheuma…

Kunishita et al Abatacept in those with RA and prev cancer (or not). Equally effective. No significant difference in 5-year malignancy but those curves look like they are diverging to me! @rheumnow #ACR22 Abstr#0255 https://t.co/1E2SXMGbqD https://t.co/gTvOOnuzo0

• Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previo…

What do you do if a person with #rheumatoidarthritis was great on 1st JAKi. It was 1st line advanced Rx @RheumNow #ACR22

@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v

OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9

OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line. 1/2 switch JAKi->TNFi 1/3 switch JAKi ->JAKi Why high proportion of JAKi cycling, when AE reason for switch low? https://t.co/APdWW7fzJE Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI

• Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A …

ACR Year in review J. Varga What drives TNF superproduction in RA? Study mice 🐁 model grafted w/ human synovial tissue suggests important role of mitochondrial stress through aspartate deficiency A potential new therapeutic target 🎯 RA? @RheumNow #ACR22 #ACRyearinreview https://t.co/lKrOn05sFp

Tissue-resident memory T cells (Trm): ☝️Do not recirculate by blood or lymphatics ☝️Can drive recurrent inflammation ☝️Fixed-drug eruption is an example CD8Trm - abundant in late stage non-inflamed RA synovium #ACR22 @RheumNow #yearinreview #RheumTwitter https://t.co/LfTI0LamkN

New 2022 EULAR Recommendations for the Management of RA The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment. https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57

• https://bit.ly/3TsSWKQ

A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA. Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality https://t.co/IYccicjcyy Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l

• Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Pro…

Yr in review #ACR22 @RheumNow 🌟GLORIA 2 yr data: 👉Pred 5mg OD vs PBO >65y/o RA ✅⬇️ disease activity (DAS28 -0.38) ✅⬇️ joint damage (sharp/van der heijde -1.7) ❌ 24% ⬆️ a/e “Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”

Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh

Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1

GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5! @RheumNow #ACR22 #yearinreview #ACRBest